Baseline severity of depression predicts antidepressant drug response relative to escitalopram

Bibliography

• Jacobsen LN, Lassen IS, Friis P, et al. Bodily symptoms in moderate and severe depression. Nord J Psychiatry 2005;60:294-8
   Web of Science ®Google Scholar
• Kessing LV. Epidemiology of subtypes of depression. Acta Psychiatr Scand 2007;115:85-9
   Web of Science ®Google Scholar
• Nemeroff CB. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psych Res 2007;41:189-206
   Google Scholar
• Miller DK. The effects of childhood physical abuse or sexual abuse in battered women's coping mechanisms: obsessive-compulsive tendencies and severe depression. J Fam Viol 2006;21:185-95
   Web of Science ®Google Scholar
• Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: Modulation by a polymorphism in the 5-HTT gene. Science 2003;301:386-9
   PubMed Web of Science ®Google Scholar
• Cervilla JA, Rivera M, Molina E, et al. The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: The PREDICT-Gene Study. Am J Med Genet 2006;141B:912-7
   PubMed Web of Science ®Google Scholar
• Cervilla JA, Molina E, Rivera M, et al. The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5-HTTLPR genotype: Evidence from the Spanish PREDICT-Gene cohort. Mol Psychiatry 2007;12:748-55
   PubMed Web of Science ®Google Scholar
• Ising M, Horstmann S, Kloiber, et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression – a potential biomarker? Biol Psychiatry 2007;62:47-54
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence Int Clin Psychopharmacol 2007;22:323-9
   PubMed Web of Science ®Google Scholar
• Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7(Suppl 1):11-7
   PubMedGoogle Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;54:1009-15
   Google Scholar
• Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19:149-55
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantinoe B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Huusom AKT, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22:1331-41
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Lam R. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-31
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:58-62
   Google Scholar
• Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;67:736-46
   PubMed Web of Science ®Google Scholar
• Khan MNS. Comparison of escitalopram a new SSRI with a TCA, clomipramine in major depressive disorder: A double blind study. Pak J Med Sci 2004;20:238-41
   Google Scholar
• Lalit V, Prakash A, Rajendra H, et al. Escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in Indian patients with unipolar depression. Ind J Psychiatry 2004;46:333-41
   PubMedGoogle Scholar
• Li J, Shen WW, Liu Y, et al. The effectiveness and safety of escitalopram in the treatment of major depression: A randomized double-blind active-drug controlled trial. Chin J Evidence Based Med Zhongguo xunzheng yixue zazhi 2006;6:552-6
   Google Scholar
• Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007;23:401-16
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Lam R. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-31
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: A meta-analysis. Curr Med Res Opin 2009;25:161-75
   PubMed Web of Science ®Google Scholar
• Bech P, Tanghoj P, Cialdella P, et al. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004;7:283-90
   PubMed Web of Science ®Google Scholar
• Montgomery DC. Design and Analysis of Experiments. John Wiley & Sons, NY; 2001
   Google Scholar
• Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006;39:180-4
   PubMed Web of Science ®Google Scholar
• Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 2006;39:128-34
   PubMed Web of Science ®Google Scholar
• Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007;23:1605-14
   PubMed Web of Science ®Google Scholar
• Yevtushenko VY, Belous AI, Yevtushenko YG, et al. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: A 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. J Clin Ther 2007;29:2319-32
   PubMed Web of Science ®Google Scholar
• El Mansari ME, Wiborg O, Mnie-Filali O, et al. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Int J Neuropsychopharmacol 2007;10:31-40
   PubMed Web of Science ®Google Scholar
• Lam RW, Andersen HF, Wade AG. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. Int Clin Psychopharmacol 2008;23:181-7
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006;21:297-309
   PubMed Web of Science ®Google Scholar
• Shelton RC, Andorn AC, Mallinckrodt CH, et al. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol 2007;22:348-55
   PubMed Web of Science ®Google Scholar
• Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007;32:86-102
   PubMed Web of Science ®Google Scholar
• Sánchez C, Bøgesø KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004;174:163-76
   PubMed Web of Science ®Google Scholar
• Linden M, Ludewig K, Munz T, et al. Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: results of a drug utilization observation study. Pharmacopsychiatry 2003;36:197-205
   PubMed Web of Science ®Google Scholar
• Burchett B, Masand PS, Patkar AA, et al. A comparison of tolerability profiles of patients with major depressive disorder receiving selective serotonin reuptake inhibitors (SSRI) in a naturalistic clinical-care setting. Poster presented at NCDEU (2006;). Available from: www.nimh.gov/research-funding/scientific-meetings/ncdeu/past/ncdeufinalupdate7-3-06.pdf
   Google Scholar
• Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 2001;15:765-76
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Reines EH, Guiton C, et al. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 2007;41:1583-92
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-7
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Hindmarch I, Huusom AKT, et al. A double-blind, randomised study of escitalopram and paroxetine in the long-term treatment of major depressive disorder. Int Clin Psychopharmacol 2006;21:159-69
   PubMed Web of Science ®Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6
   PubMed Web of Science ®Google Scholar
• Saikali K, Bose A, Korotzer A, et al. An evaluation of LOCF and MMRM statistical methods in the analysis of major depression clinical studies. Int J Neuropsychopharmacol 2006;9(suppl 1):S236
   Google Scholar
• Bielski RJ, Ventura D, Chang CC. A double-blind comparison of venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-6
   PubMed Web of Science ®Google Scholar
• Forest Laboratories. Flexible dose comparison of the safety and efficacy of escitalopram and fluoxetine in the treatment of major depressive disorder. (2005) Summary Available from: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_SCT-MD-16_final.pdf
   Google Scholar
• Alexopoulos GS, Privitera W, Ventura D, et al. Fixed dose of escitalopram (10mg/day) and a flexible dosing regimen of sertraline (50-200mg/day) in a randomised, double-blind comparison in depressed patients. World J Biol Psychiatry 2004;5(Suppl 1):97
   Google Scholar
• Alexopoulos GS, Gordon J, Zhang D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Neuropsychopharmacology 2004;29 (suppl):S87
   Google Scholar
• Colonna L, Andersen HF, Reines EH. A randomised, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005;21:1659-68
   PubMed Web of Science ®Google Scholar
• Mao PX, Tang YL, Jiang F, et al. Escitalopram in major depressive disorder: a multi-center, randomized, double-blind fixed-dose parallel trial in a Chinese population. Depress Anxiety 2008;25:46-54
   PubMed Web of Science ®Google Scholar
• Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007;27:481-92
   PubMed Web of Science ®Google Scholar
• Kasper S, de Swart H, Andersen HF. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005;13:884-91
   PubMed Web of Science ®Google Scholar